Development of a Risk‐Estimation Model for Identifying Patients at Risk of Early Skeletal Muscle Mass Loss in Chronic Liver Disease
Hepatology Research · 2026-11 · 56 (11) · 1696-1702
DOI: 10.1111/hepr.70245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 15.07.2026. Verfasst von Atsushi Hiraoka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background and Aim Sarcopenia is associated with poor outcomes in patients with chronic liver disease (CLD), but current screening based on reduced muscle strength may fail to identify early skeletal muscle loss. This study aimed to develop a risk‐estimation model for identifying patients at risk of early skeletal muscle mass loss before patients meet the diagnostic criteria for overt sarcopenia.
Methods
This retrospective study included 1276 CLD patients who underwent handgrip strength testing and computed tomography‐based skeletal muscle index (SMI) assessment between 2015 and 2026. SMI ratio and grip ratio were defined as relative deviations from sex‐specific reference values established by the Japan Society of Hepatology. Early skeletal muscle mass loss was defined as an SMI ratio < 0.05. A multivariable logistic regression model incorporating grip ratio, age, sex, platelet count, albumin‐bilirubin score, creatinine, body mass index, hepatocellular carcinoma status, and the interaction between grip ratio and sex was developed (MYO‐SCAN score).
Results
The model demonstrated good discrimination for identifying patients with an SMI ratio < 0.05 with an area under the receiver operating characteristic curve (AUC) of 0.847. The optimal cutoff value was 0.435, yielding sensitivity and specificity of 0.777 and 0.764, respectively. Risk‐estimation performance was significantly superior to grip ratio alone (AUC 0.847 vs. 0.614, p < 0.001). Bootstrap validation showed minimal optimism with an optimism‐corrected AUC of 0.843.
Conclusion
The MYO‐SCAN score may facilitate early identification of CLD patients at risk of skeletal muscle mass loss, including those who may be overlooked by grip‐strength–based screening.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
- Department of Human Immunology and Translational Research, National Institute of Global Health and Medicine, Japan Institute for Health Security, Shinjuku, Japan.
ORCID-Profile: Atsushi Hiraoka, Hideko Ohama, Fujimasa Tada, Osamu Yoshida, Masashi Hirooka, Masanori Abe, Tomoyuki Ninomiya, Sachiyo Yoshio, Yoichi Hiasa
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Hiraoka, A., Ohama, H., Tada, F., Tange, K., Yoshida, O., Hirooka, M., Abe, M., Ninomiya, T., Yoshio, S., & Hiasa, Y. (2026). Development of a Risk‐Estimation Model for Identifying Patients at Risk of Early Skeletal Muscle Mass Loss in Chronic Liver Disease. Hepatology Research, 56(11), 1696-1702. https://doi.org/10.1111/hepr.70245
Vancouver
Hiraoka A, Ohama H, Tada F, Tange K, Yoshida O, Hirooka M, et al. Development of a Risk‐Estimation Model for Identifying Patients at Risk of Early Skeletal Muscle Mass Loss in Chronic Liver Disease. Hepatology Research. 2026;56(11):1696-1702. doi:10.1111/hepr.70245
BibTeX
@article{Hiraoka2026,
author = {Hiraoka, Atsushi and Ohama, Hideko and Tada, Fujimasa and Tange, Kazuhiro and Yoshida, Osamu and Hirooka, Masashi and Abe, Masanori and Ninomiya, Tomoyuki and Yoshio, Sachiyo and Hiasa, Yoichi},
title = {Development of a Risk‐Estimation Model for Identifying Patients at Risk of Early Skeletal Muscle Mass Loss in Chronic Liver Disease},
journal = {Hepatology Research},
year = {2026},
volume = {56},
number = {11},
pages = {1696--1702},
doi = {10.1111/hepr.70245}
}
EUVIMED